These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 6733704)

  • 1. Mitoxantrone in malignant melanoma.
    Presant CA; Gams R; Bartolucci A
    Cancer Treat Rep; 1984 Jun; 68(6):903-5. PubMed ID: 6733704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
    Arseneau JC; Schoenfeld DA; Borden EC
    Invest New Drugs; 1986; 4(1):53-6. PubMed ID: 3700041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma.
    Berman E; Casper ES; Howard J; Wittes RE
    Cancer Treat Rep; 1984 Apr; 68(4):679-80. PubMed ID: 6585272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
    Coates AS; Bishop J; Mann GJ; Raghavan D
    Eur J Cancer Clin Oncol; 1986 Jan; 22(1):97-100. PubMed ID: 3754214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phase II study of mitoxantrone for hematologic malignancies].
    Ueoka H; Ueno K; Yamane T; Toyoda K; Endo H; Nishihara R; Takahashi I; Ohnoshi T; Kitajima K; Kimura I
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2399-402. PubMed ID: 6639101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase II study of mitoxantrone].
    Tada A; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Adachi K; Nakada H; Okada Y
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1649-54. PubMed ID: 6476838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: a Southwest Oncology Group Study.
    Von Hoff DD; Chen T; Clark GM; Callahan SK; Livingston R
    Cancer Treat Rep; 1983 Apr; 67(4):403-4. PubMed ID: 6303588
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
    Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
    Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of mitoxantrone in advanced colorectal cancer.
    Bonnem EM; Mitchell EP; Woolley PV; Smith FP; Neefe J; Smith L; Schein PS
    Cancer Treat Rep; 1982 Nov; 66(11):1995-6. PubMed ID: 7139642
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.
    Taylor SA; Tranum BT; Von Hoff DD; Costanzi JJ
    Invest New Drugs; 1985; 3(1):67-9. PubMed ID: 3988458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a Southeastern Cancer Study Group Trial.
    DeSimone PA; Gams R; Birch R
    Cancer Treat Rep; 1986 Aug; 70(8):1043-4. PubMed ID: 3524836
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II trial of mitoxantrone in refractory germ cell tumors: a trial of the Southeastern Cancer Study Group.
    Williams SD; Birch R; Gams R; Irwin L
    Cancer Treat Rep; 1985 Dec; 69(12):1455-6. PubMed ID: 3000593
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
    Cowan JD; Von Hoff DD; McDonald B; Talley RW; McCracken JD; Chen T
    Cancer Treat Rep; 1982 Sep; 66(9):1779-80. PubMed ID: 7116355
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial.
    Gams RA; Nelson O; Birch R
    Cancer Treat Rep; 1986 Jul; 70(7):921-2. PubMed ID: 3521848
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.
    Taylor SA; Von Hoff DD; Baker LH; Balcerzak SP
    Cancer Treat Rep; 1984 Jun; 68(6):919-20. PubMed ID: 6733708
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical and clinical pharmacologic studies of mitoxantrone.
    Stewart JA; McCormack JJ; Krakoff IH
    Cancer Treat Rep; 1982 Jun; 66(6):1327-31. PubMed ID: 7083236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluation of mitoxantrone in patients with bronchogenic carcinoma: a Southeastern Cancer Study Group trial.
    Kramer BS; Gams R; Birch R; Einhorn L; Buchanan R
    Cancer Treat Rep; 1984 Oct; 68(10):1295-6. PubMed ID: 6525601
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
    Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
    Am J Clin Oncol; 1983 Feb; 6(1):45-8. PubMed ID: 6837506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
    Alberts DS; Balcerzak SP; Bonnet JD; Stephens RL
    Cancer Treat Rep; 1985 Nov; 69(11):1321-3. PubMed ID: 4092195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
    Bull FE; Von Hoff DD; Balcerzak SP; Stephens RL; Panettiere FJ
    Cancer Treat Rep; 1985 Feb; 69(2):231-3. PubMed ID: 3882233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.